Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 8-9, 2004, Pages 1351-1356

  Hubeek, I ^a   Peters, G J ^a   Broekhuizen, A J F ^a   Talianidis, I ^b   Schouten Van Meeteren, A Y N ^a   Van Wering, E R ^c   Gibson, B ^d   Creutzig, U ^e   Kaspers, G J L ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Inst of Molec Biol and Biotech   (Greece)

^c DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

^d MRC Childhood Leukaemia Working Party   (United Kingdom)

^e AML BFM Study Group   (Germany)

Author keywords

Deoxycytidine kinase; Immunocytochemistry; Pediatric malignancies

Indexed keywords

CYTARABINE; CYTIDINE DERIVATIVE; DEOXYCYTIDINE DERIVATIVE; DEOXYCYTIDINE KINASE; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; BRAIN TUMOR; CHILD; CHILDHOOD CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ASSAY; ENZYME MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; RETINOBLASTOMA; TUMOR CELL;

ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; COLORING AGENTS; CYTARABINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA; NEOPLASMS; RETINOBLASTOMA; TETRAZOLIUM SALTS; THIAZOLES;

ARA;

EID: 10344240923     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-200027613     Document Type: Conference Paper

References (10)

1. Peters, G.J.; Ackland, S.P. New antimetabolites in preclinical and clinical development. Expert Opin. Investig. Drugs 1996, 5, 637-679.
2. Grant, S. Ara-C: cellular and molecular pharmacology. Adv. Cancer Res. 1998, 72, 197-233.
3. Plunkett, W.; Gandhi, V. Cellular pharmacodynamics of anticancer drugs. Semin. Oncol. 1993, 20, 50-63.
4. Bhalla, K.; Nayak, R.; Grant, S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine. Cancer Res. 1984, 44, 5029-5037.
5. Zwaan, C.M.; Kaspers, G.J.; Pieters, R.; Ramakers-Van Woerden, N.L.; den Boer, M.L.; Wunsche, R.; Rottier, M.M.; Hahlen, K.; van Wering, E.R.; Janka-Schaub, G.E.; Creutzig, U.; Veerman, A.J. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 2000, 96, 2879-2886.
6. Schouten-van Meeteren, A.Y.; van der Valk, P.; van der Linden, H.C.; Moll, A.C.; Imhof, S.M.; Huismans, D.R.; Loonen, A.H.; Veerman, A.J. Histopathologic features of retinoblastoma and its relation with in vitro drug resistance measured by means of the MTT assay. Cancer 2001, 92, 2933-2940.
7. Schouten van Meeteren, A.Y.; van der Valk, P.; van der Linden, H.C.; van Ouwerkerk, W.J.; Broekhuizen, A.J.; Huismans, D.R.; Loonen, A.H.; Veerman, A.J. Features of proliferation and in vitro drug resistance in central primitive neuroectodermal tumours. Neuropathol. Appl Neurobiol. 2002, 28, 200-209.
8. Kaspers, G.J.; Pieters, R.; Van Zantwijk, C.H.; De Laat, P.A.; De Waal, F.C.; Van Wering, E.R.; Veerman, A.J. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br. J. Cancer 1991, 64, 469-474.
9. Pieters, R.; Loonen, A.H.; Huismans, D.R.; Broekema, G.J.; Dirven, M.W.; Heyenbrok, M.W.; Hahlen, K.; Veerman, A.J. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990, 76, 2327-2336.
10. Kroep, J.R.; Loves, W.J.; van der Wilt, C.L.; Alvarez, E.; Talianidis, L.; Boven, E.; Braakhuis, B.J.; van Groeningen, C.J.; Pinedo, H.M.; Peters, G.J. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 2002, 1, 371-376.